CN110437333A - SFTSV inhibitor and its application - Google Patents

Abstract

The invention discloses a kind of SFTSV inhibitor, the SFTSV inhibitor is the monoclonal antibody for SFTSV, the sequence of the CDR-H3 wherein provided in sequence of the variable domains of heavy chain comprising the CDR-H1 provided in SEQ ID NO:1, the sequence of the CDR-H2 provided in SEQ ID NO:2 and SEQ ID NO:3, and the sequence of the CDR-L3 provided in sequence of the variable domains of light chain comprising the CDR-L1 provided in SEQ ID NO:4, the sequence of the CDR-L2 provided in SEQID NO:5 and SEQ ID NO:6.The present invention also extends to the therapeutic use, composition and the method for detecting SFTSV of the inhibitor.

Description

SFTSV inhibitor and its application

Technical field

The invention belongs to molecular immunology field, it is related to a kind of SFTSV inhibitor and its application.

Background technique

Fever companion thrombocytopenic syndromes (severe fever with thrombocytopenia syndrome, SFTS) belong to novel tick and pass entomophila Hemorrhagic fever, be the very thin Viraceae sand fly of bunyavirus mesh sand fly by new discovery and name The new hair of one kind, Natur al foca caused by Tobamovirus virus-fever companion's thrombocytopenic syndromes virus (SFTSV) infection, Acute infectious disease is commonly called as " tick parasitosis ", from 2009 since China Middle Eastern is found, with adding for monitoring dynamics By force, many places report confirmed cases in succession, Japan, South Korea, the U.S. and United Arab Emirates etc. also when have medical record report Road, SFTS constitute global human health and seriously threaten.

Bunyavirus mesh member is propagated by Vector factors, such as tick, mite, mosquito, mouse mostly, causes area or global stream Row.Mainly there are Hantaan virus (Hantaan virus section) and xinjiang hemorrhagic fever virus (Nairovirus section) to cause region stream in China Row.Chinese Center for Disease Control and Prevention in 2011 isolates SFTSV from SFTS acute stage sufferer blood, by gene order ratio To and homology analysis, assert that the virus belongs to Phlebovirus, the viral genome has been resolved at present: by small (S), in (M), big (L) three sub-thread strand RNA segment compositions, viral genome 3 ' end similar to other viruses of bunyavirus mesh With the complementation of 5 ' end sequences.S segment category ambisense RNA, main code Nuclear Protein NP and non-structural protein NSS, L fragment coding by The RNA polymerase that the RNA of 2084 amino acid compositions is relied on；M fragment coding has the memebrane protein precursor of 1073 amino acid, turns over Two glycoprotein of Gn and Gc that albumen enzyme modification is formed in host cell after translating have mediated the overall process of virus infection host, are Stimulation of host generates the critical antigen molecule body of neutralizing antibody, and Gn and Gc have become the important target spot of current SFTS vaccine research.

SFTS patient usually has tick sting history, and typical performance is onset urgency after infection, and high fever is with malaise, head Bitterly, muscle arthrosis is ached, and typical clinical feature is that leucocyte and blood platelet are substantially reduced, and transaminase increases, and serum lactic is de- Hydrogen enzyme is significantly raised, prolonged prothrombin, and the electrolyte such as sodium, potassium, chlorine are relatively low.Case mostly moves in knob, first Morbidity example is mostly the middle-aged and the old for having field work to undergo, and average case fatality rate is about 10%, and the cause of death is mainly multi viscera function It can failure.The case is mostly to distribute, and can also clustering of disease in family be caused to break out, and there are serious human-to-human transmission phenomenons by SFTS, contacts patient Blood or secretion can infect SFTSV.

Since the disease is one newly from right epidemic disease source sexually transmitted disease, epidemic situation can not disappear in a short time；It there is no at present effective For vaccine for preventing, people has infected SFTSV, also without specific drug for clinic, mainly based on symptomatic treatment；The disease clinic originates Symptom is no different with common influenza, and patient focuses mostly in rural area, has inconvenient traffic, and hygiene medical treatment is horizontal weak, until making a definite diagnosis, The state of an illness develops to viremia virusemia, multiple organs failure mostly, and clinic can only take symptomatic treatment means at this time.And as chemotherapy Supplement, good effect has been shown by the measure of antibody-mediated prevention and treatment virus infection, application prospect obtains specially The approval of family.Antibody can pass through blocking virus as most important antiviral immunity medium a kind of in human body, antibody molecule Combination, activating macrophage, NK cell of grain and its receptor etc. kills the number of mechanisms such as cell, activating complement to kill, remove Virion and infected cell.Antibody preparation can not only neutralize a large amount of virus in patient body, reduce load, lapse to disease Feelings such as accompany and attend to, medical staff carries out urgent passive immunity to the Close contacts of patient, prevent two generations, three generations the infected from going out It is existing.

Studies have shown that clinically using the rehabilitation human plasma of virus-specific, virus can be effectively neutralized, prevents virus in body Interior each organ diffusion, avoids the multiple organs failure that lethal occurs, also plays important function to lapsing to for patient's course of disease.But it is mostly anti- Blood plasma not only limited source, while its clinical application is also by being such as difficult to Quality Control, mismatch for receptor blood group, potential infect The limitation of the conditions such as sex factor.The preparation of source of mouse monoclonal antibody is simple, and cure mechanism is clear, but its heterologous hinder it is intracorporal in people Using.And human monoclonal antibody can effectively overcome the above problem.

The anti-SFTSV antibody that does not list still both at home and abroad at present, thus establish and develop it is with independent intellectual property rights with Detection and diagnosis and treatment articles based on antibody, have important practical significance for a variety of diseases related interventions.

Summary of the invention

The application uses and constructs the source of people immunity phage antibody library an of high capacity, and with the SFTSV- of purifying Gn albumen is target, is screened human single chain variable fragments antibody segment (single chain variable fragment, scFv), obtains three Kind source of people scFv antibody molecule, is named as 4-6,2F6,1B2.Applied molecular biology means to three kinds of single chain antibody fragments into The full molecularization of row is gene constructed, and eukaryotic expression 4-6IgG1,2F6IgG1,1B2 IgG1.Further study showed that three kinds of lists It is anti-to have stronger combination activity and neutralization to SFTS virus.

Based on above the study found that protected object of the present invention is as follows:

The present invention provides a kind of SFTSV inhibitor, the SFTSV inhibitor be for SFTSV albumen specificity it is anti- Body.In specific embodiments of the present invention, the SFTSV inhibitor is the monoclonal antibody specific for SFTSV albumen.

SFTSV inhibitor of the invention includes:

(1) heavy chain CDR2 shown in heavy chain CDR1, SEQ ID NO:2 shown in SEQ ID NO:1, SEQ ID NO:3 institute The heavy chain CDR3 shown；And/or

(2) light chain CDR2 shown in light chain CDR1, SEQ ID NO:5 shown in SEQ ID NO:4, SEQ ID NO:6 institute The light chain CDR3 shown.

As one aspect of the present invention, SFTSV inhibitor of the invention includes:

(1) heavy chain variable region, the heavy chain variable region have amino acid sequence shown in SEQ ID NO:7；And/or

(2) light chain variable region, the light chain variable region have amino acid sequence shown in SEQ ID NO:8.

SFTSV inhibitor recited above is referred to as parental generation suppression by the functional variety of following inhibitor for convenience of explanation Preparation.

SFTSV inhibitor of the invention can be complete immunoglobulin molecules, and immunoglobulin molecules, which can be, appoints What type (for example, IgG, IgE, IgM, IgD, IgA and IgY) class (for example, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) Or subclass.In a specific embodiment of the present invention, the complete immunoglobulin molecules of SFTSV inhibitor are IgG1 types.

SFTSV inhibitor of the invention can also be antigen-binding fragment, including but not limited to Fab segment, Fab' segment, Fab'-SH segment, F (ab')²Segment, Fd segment, Fv segment, double antibody, scFv (scFv) only contain a light chain variable The single chain polypeptide in area, the single chain polypeptide of three CDR containing light chain variable region are only single-stranded more containing heavy chain variable region Peptide, the single chain polypeptide of three CDR containing a heavy chain variable region, heavy chain variable region and VHH.In specific embodiments of the present invention In, SFTSV inhibitor can be scFv.

SFTSV inhibitor of the invention further includes the functional variety of mentioned-above SFTSV inhibitor, and the function becomes Body includes but is not limited to that primary structural sequence is substantially similar, still contains the not found external or body for example in parental generation inhibitor The derivative of interior chemistry and/or biochemical modification.This modification includes that second phthalein, phthalein, nucleotide or nucleotide are derivative The covalent attachment of object, the covalent attachment of lipid or lipid derivate, crosslinking, disulfide bond formation, glycosylation, hydroxylating, methyl Change, oxidation, Pegylation, proteolysis processing, phosphorylation etc..In other words, the amino acid and/or nucleosides of parental generation inhibitor Modification in acid sequence does not significantly affect or changes by described nucleotide sequence coded or containing the amino acid sequence The binding characteristic of the inhibitor, i.e., the described inhibitor remain to identify and combine its target position.

The functional variety can have conserved sequence modification, including amino acid substitution, addition and missing.These modifications can To be imported by the known standard technique in this field, such as the mutagenesis that directed mutagenesis and random PCR mediate, and may include natural And unnatural amino acid.

Conserved amino acid replaces including wherein amino acid residue by another amino with similar structure or chemical property The substitution of sour residue displacement.The family of amino acid residue with similar side chain oneself limited in the art.These families packet Include amino acid (such as lysine, arginine, histidine) with basic side chain, acidic side chains (such as aspartic acid, Glutamic acid), without charge polarity side chain amino acid (such as asparagus fern phthalein amine, paddy ammonia phthalein amine, serine, threonine, tyrosine, half skin Propylhomoserin, tryptophan), nonpolar side chains (such as glycine, alanine, valine, leucine, isoleucine, dried meat ammonia Acid, phenylalanine, methionine), branched side chains (such as threonine, valine, isoleucine) and aromatic side chain Amino acid (such as tyrosine, phenylalanine, tryptophan).It will be appreciated that also can be used in addition to above-mentioned family it Outer other amino acid residue families mode classifications.In addition, variant can have a non-conservative amino acid substitution, for example, amino acid by Another radical amino acid replacement with different structure or chemical property.It is similar it is small variation may also comprise amino acid deletions or Person's insertion, or both.It is can be found that using computer program well known in the art and determines which amino acid residue can be by Replace, the guidance of insertion or missing without eliminating immunologic competence.

In addition, functional variety may include truncation of the amino acid sequence at amino terminal or carboxyl terminal or this both ends Body.Functional variety of the invention can have identical or different, higher or lower binding affinity compared with parental generation inhibitor, But it remains to combine SFTSV albumen.Hereafter, when using term " inhibitor ", it is also covered by the functional variety of the inhibitor.

The functional variety also includes the modification to hypervariable region, and hypervariable region is comprising the amino acid residue from CDR and comes from The amino acid residue of hypervariable loop.Functional variety and parental generation inhibitor described herein within the scope of the present invention has at least about 50% to about 99%, be preferably at least about 60% to about 99%, more preferably at least about 70% to about 99%, even more Preferably at least about 80% to about 99%, most preferably at least about 90% to about 99%, particularly at least about 95% to About 99%, and the amino acid sequence homology of especially at least about 97% to about 99%.

Computerized algorithm well known by persons skilled in the art such as Gap or Bestfit can be used for most preferably arrays of amino acid Sequence is to compare and clearly similar or identical amino acid residue.Functional variety can be known by using this field Common molecular biology method changes parental generation inhibitor or part of it and obtains, the method includes but be not limited to fallibility PCR, Mutagenesis, direct mutagenesis and the heavy chain and/or light chain of oligonucleotides guidance reorganize method.

The present invention provides the nucleic acid molecules for encoding mentioned-above SFTSV inhibitor.The nucleic acid of encoding heavy chain CDR1 point Subsequence is as shown in SEQ ID NO:9, and the sequence of nucleic acid molecules of encoding heavy chain CDR2 is as shown in SEQ ID NO:10, encoding heavy chain The sequence of nucleic acid molecules of CDR3 is as shown in SEQ ID NO:11, the sequence of nucleic acid molecules of encoding heavy chain variable region such as SEQ ID NO: Shown in 12；The sequence of nucleic acid molecules of light chain CDR1 is encoded as shown in SEQ ID NO:13, encodes the nucleic acid molecules sequence of light chain CDR2 Column encode the sequence of nucleic acid molecules of light chain CDR3 as shown in SEQ ID NO:15 as shown in SEQ ID NO:14, and coding light chain can Become the sequence of nucleic acid molecules in area as shown in SEQ ID NO:16.

The nucleic acid molecules are further included in the antibody under stringent condition with coding comprising heavy chain or sequence of light chain The nucleotide sequence of making nucleic acid molecular hybridization.

It will be appreciated by persons skilled in the art that the functional variety of these nucleic acid molecules is also a part of the invention.Function becomes Body is such nucleic acid sequence, by using standard genetic code can by its directly translation with provide with from parent nucleic acid molecules The identical amino acid sequence of the sequence of middle translation.

Once obtaining related sequence, so that it may obtain related sequence in large quantity with recombination method.This is usually will It is cloned into carrier, then is transferred to cell, then the isolated related sequence from the host cell after proliferation by conventional method.

In addition, related sequence can be also synthesized with artificial synthesized method, when especially fragment length is shorter.In general, logical After first synthesizing multiple small fragments, it is then attached the very long segment of available sequence again.

At present, it is already possible to obtain encoding completely by chemical synthesis inhibitor of the invention (its segment or its spread out Biology) nucleic acid sequence.Then the nucleic acid sequence can be introduced to various existing DNA moleculars as known in the art (or as carried Body) and cell in.In addition, can will be also mutated in the sequence of inhibitor incorporated in the present invention by chemical synthesis.

The present invention also provides a kind of recombinant vectors including mentioned-above nucleic acid molecules, in addition to mentioned-above nucleic acid Except molecule, recombinant vector further includes the regulating and controlling sequence being operatively connected with the sequence of nucleic acid molecules.

These recombinant vectors can be used for converting host cell appropriate, allow it to expression nucleic acid molecules or albumen Matter.

The carrier includes cloning vector or expression vector.Cloning vector is used for amplifier nucleic acid molecule, and expression vector is used In the protein of expression nucleic acid molecule encoding.

The present invention also provides a kind of recombinant cell containing mentioned-above nucleic acid molecules or mentioned-above carrier.

Recombinant cell can be prokaryotic cell, such as bacterial cell；Or low eukaryocyte, such as yeast cells；Or it is high Equal eukaryocytes, such as mammalian cell.Representative example has: Escherichia coli, streptomyces；The bacterium of salmonella typhimurium Cell: fungal cell's such as yeast；Plant cell；The insect cell of drosophila S2 or Sf9；CHO, COS, 293 cell or Bowes are black The zooblast etc. of plain oncocyte.

The pharmaceutical composition of the present invention provides a kind of mentioned-above SFTSV inhibitor including therapeutically effective amount.

Further, described pharmaceutical composition further includes pharmaceutically acceptable carrier.

The term as used herein " pharmaceutically acceptable " refer to when biomolecule ontology and composition suitably give animal or When people, unfavorable, allergy or other adverse reactions that they will not be generated." pharmaceutically acceptable carrier " used herein is answered It, can the blended effect without composition is greatly lowered in general when compatible with inhibitor of the invention.

The specific example that can be used as pharmaceutically acceptable carrier or some substances of its component is carbohydrate, such as lactose, Portugal Grape sugar and sucrose；Starch, such as cornstarch and potato starch；Cellulose and its derivates, as sodium carboxymethylcellulose, ethyl are fine Dimension element and methylcellulose；Tragacanth powder；Malt；Gelatin；Talcum；Solid lubricant, such as stearic acid and magnesium stearate；Sulphur Sour calcium；Vegetable oil, such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil and cupu oil；Polyalcohol, such as propylene glycol, sweet Oil, D-sorbite, mannitol and polyethylene glycol；Alginic acid；Emulsifier, such as Tween；Wetting agent, such as NaLS； Toner；Flavoring agent；Tablet agent, stabilizer；Antioxidant；Preservative；Apirogen water；Isotonic salting liquid；And phosphate buffer Deng.

Various dosage forms can be made in composition of the invention as needed, and can be by doctor according to patient category, age, weight Substantially the factors such as disease condition, administration mode determine that the dosage beneficial to patient is administered.Administration mode can for example adopt With injection or other therapeutic modalities.

It can include other anti-SFTSV drugs with the drug of pharmaceutical composition use in conjunction of the invention.

The present invention also provides a kind of immunoconjugates, the immunoconjugates include at least one inhibitor described herein And further include the detectable part/substance of at least one marker.Detectable part/substance includes but is not limited to Enzyme, prothetic group, fluorescent material, luminescent material, bioluminescent material, radioactive material, positron emitting metal and on-radiation Paramagnetic metal ion.

In order to detect and/or analyze and/or diagnostic purpose is used to mark the label of inhibitor dependent on the specific inspection that uses Survey/analysis/diagnostic techniques and/or method such as immunohistochemical staining (tissue) sample, flow cytometry, laser are swept Retouch cytometry detection, fluorescence immunoassay, enzyme linked immunosorbent assay (ELISA) (ELISA), radiommunoassay (RIA), biology Measure (such as phagocytosis measurement), Western blotting application etc..For detection/analysis/diagnostic techniques known in the art and/ Or method is suitably marked and is well known to those skilled in the art.

It is generated except immunoconjugates except through direct or indirect (such as passing through connector) conjugation chemistry, it is described immune Conjugate can be used as fusion protein and generate, and the fusion protein includes inhibitor and suitable label of the invention.Fusion Albumen can be generated by means known in the art, such as by building nucleic acid molecules and then express the nucleic acid molecules Recombination generates, and the nucleic acid molecules include the nucleotide sequence of in-frame coding inhibitor and the core for encoding suitable marker Nucleotide sequence.

The present invention also provides the testing products of SFTSV in measurement sample a kind of, and the product includes mentioned-above SFTSV inhibitor.

Further, the product includes but is not limited to detection reagent, kit, chip or test paper.All includes front institute That states inhibitor is capable of detecting when that the testing product of SFTSV is included within the scope of the present invention.

SFTSV inhibitor of the invention, and anti-SFTSV antibody can be called, any one of multiple technologies can be passed through Preparation.In general, antibody can be generated by cell culture technology, including monoclonal antibody is generated by routine techniques, or pass through By antibody gene, heavy chain and/or light chain are transfected into suitable bacterium or mammalian cell host, to allow the production of antibody It is raw, wherein the antibody can be recombination.The various forms of term " transfection " is intended to include commonly used in introducing exogenous DNA The various technologies of protokaryon or eukaryotic host cell, such as electroporation, calcium phosphate precipitation, DEAE- glucan transfection etc..Although can be with Antibody of the invention is expressed in protokaryon or eukaryotic host cell, it is preferred that expressing antibody in eukaryocyte, and optimal Be selected in mammalian host cell and express because this eukaryocyte (especially mammalian cell) be more likely to it is thinner than protokaryon Born of the same parents' assembling and the correct folding of secretion and immunocompetent antibody.

For the Exemplary mammals host cell of expressing recombinant antibody, the present invention includes together with DHFR selected marker The Chinese hamster ovary (Chinese hamster ovary celI) used, NS0 myeloma cell, COS cell, HEK 293T cell and SP2 cell.As general When the recombinant expression carrier of encoding antibody genes introduces mammalian host cell, by the way that host cell culture is enough to allow to resist A period of time that body is expressed in host cell, or it is highly preferred that by antibody-secreting to the culture medium for cultivating host cell.It can be with Antibody is recycled from culture medium using standard protein purification method.

Host cell can also be used for generating functional antibody fragment, such as Fab segment or scFv molecule.On it should be appreciated that State the variation of program within the scope of the invention.For example, it may be desired to the function for the light chain and/or heavy chain for encoding antibody of the present invention The DNA transfection host cell of energy segment.Recombinant DNA technology can also be used for removing some or all of coding one of light chains and heavy chain or The DNA of the two is not necessary to combining interested antigen.The molecule expressed from this truncated DNA molecular also includes In antibody of the invention.Furthermore, it is possible to bifunctional antibody be generated, wherein a heavy chain and a light chain are antibody of the invention (that is, in conjunction with SFTSV albumen), and another heavy chain and light chain are specific for the antigen in addition to SFTSV albumen.

The method of preparation monoclonal antibody is related to the preparation of immortality cell, can generate the antibody with required specificity Cell line.Such cell line can be generated from the splenocyte for being obtained from immune animal.It can be noted earlier with immune animal productiong Inhibitor or its segment and/or variant.

Monoclonal antibody can be separated from the supernatant of the hybridoma of growth.Furthermore, it is possible to be mentioned using various technologies High yield, such as hybridoma cell line is injected into the cavum peritoneale of suitable vertebrate host (such as mouse).Then may be used To harvest monoclonal antibody from ascites fluid or blood.Pollutant can pass through routine techniques such as chromatography, gel filtration, precipitating It is removed from antibody with extracting.Affinity chromatography is to can be used for the example of the method for antibody purification.

It is mentioned-above the method includes applying the present invention provides a kind of adjusting SFTSV activity or horizontal method SFTSV inhibitor, perhaps application includes the pharmaceutical composition or the mentioned-above packet of application of SFTSV inhibitor noted earlier Include the nucleic acid molecules for encoding the SFTSV inhibitor and the carrier including the nucleic acid molecules.

The present invention provides a kind of methods of prevention or treatment SFTSV infection.It is of the invention the method includes applying SFTSV inhibitor, perhaps application includes the pharmaceutical composition of SFTSV inhibitor or application includes coding SFTSV inhibitor Nucleic acid molecules and carrier or cell including the nucleic acid molecules.

The present invention also provides the methods of SFTSV in detection or measurement sample a kind of.This method includes making sample and this hair Bright SFTSV inhibitor contact.

The present invention also provides mentioned-above SFTSV inhibitor answering in the product of preparation detection or measurement SFTSV With.

The product includes mentioned-above SFTSV inhibitor；The product includes but is not limited to detection reagent, reagent Box, chip or test paper.All includes that mentioned-above SFTSV inhibitor is capable of detecting when that the product of SFTSV is included in this hair Within the scope of bright.

The present invention also provides mentioned-above SFTSV inhibitor to prepare answering in mentioned-above immunoconjugates With.

The present invention also provides mentioned-above SFTSV inhibitor to prepare answering in mentioned-above pharmaceutical composition With.

The present invention also provides mentioned-above SFTSV inhibitor to prepare the application in following drug:

(1) SFTSV activity or horizontal drug are adjusted；

(2) application in preparation and in the drug of SFTSV virulence；

(3) application in the drug for preparing anti-SFTSV infection；

(4) application in the drug of disease caused by being infected in preparation prevention or treatment by SFTSV.

The present invention also provides mentioned-above pharmaceutical compositions to prepare the application in following drug:

(1) SFTSV activity or horizontal drug are adjusted；

(2) application in preparation and in the drug of SFTSV virulence；

(3) application in the drug for preparing anti-SFTSV infection；

(4) application in the drug of disease caused by being infected in preparation prevention or treatment by SFTSV.

Unless otherwise defined, all technical and scientific terms used herein has usual with those of ordinary skill in the art The identical meaning understood.If any conflict, this document (including definition) will be controlled.Preferred method and the following institute of material It states, although with the similar or equivalent practice for use in the present invention of method and material or test described herein.The institute being mentioned above There are publication, patent application, patent and other bibliography to be incorporated herein in its entirety by reference.Material disclosed herein, Method and embodiment are merely illustrative, rather than restrictive.

The term as used herein " monoclonal antibody " refers to the antibody obtained from a kind of substantially uniform group, except a small number of possible Outside the existing mutation naturally occurred, the single antibody for including in the group is identical.Modifier " monoclonal " only indicates anti- The characteristic of body is obtained from substantially uniform antibody population, this cannot be construed to need to be produced with any specific process anti- Body.

The term as used herein " application " is abutment and/or delivering SFTSV inhibitor to obtain desired effect. SFTSV inhibitor can be applied to subject in many ways, including but not limited to oral, eye, nose, intravenously, part, Aerosol, suppository etc., and can be applied in combination.

Terms used herein " effective quantity " refer to the effective drug dose in required time, to realize required dosage Treatment results.Effective dose can be determined by those skilled in the art, and can be according to the morbid state of individual, age, property Not and the factors such as weight and change the ability of reaction needed for drug causes in individual.The term used herein also refers to dynamic Object, mammal, mammal or the mankind, such as reduce and/or inhibit the function of estrogen receptor.Therapeutically effective amount can be with One or many applications are (for example, medicament can be used as prophylactic treatment or any phase treatment in progression of disease, in symptom Before or after etc.), application or dosage are given, and not it is expected be limited to specific preparation, combination or administration method.Administration Number and dosage depend on several factors, such as the target for the treatment of, subject etc., and can be easy by those skilled in the art Ground determines.

" sample " of the invention can be blood, tissue, urine, serum, blood plasma, amniotic fluid, cerebrospinal fluid, placenta cells or group It knits, endothelial cell, the sample of leucocyte or monocyte.Sample can be obtained directly from patient or can be pre-processed, such as logical Filtering is distilled, and is extracted, and is concentrated, centrifugation, the inactivation of interfering component, addition reagent etc., to modify sample.

Any cell type, tissue or body fluid can be used to obtain sample.Such cell type, tissue and fluid can To include histotomy, such as biopsy and postmortem sample, for the frozen section that histology purpose obtains, blood (such as Whole blood), blood plasma, serum, phlegm, excrement, tears, mucus, saliva, BAL fluid BAL) fluid, hair, skin is red Cell, blood platelet, interstitial fluid, ocular lens fluid, celiolymph, sweat, nose liquid, synovia, menstruation, amniotic fluid, sperm etc..Cell class Type and tissue may also comprise lymph fluid, gastro-intestinal Fluid, gynaecology's liquid, urine, peritoneal fluid, cerebrospinal fluid, the liquid collected by vaginadouche Body or the liquid collected by vaginadouche.Tissue or cell type can be provided by removing cell sample from animal, But it can also be by using the cell being previously separated (for example, being separated by another person, in another time and/or for another Purpose) Lai Shixian.Also archive tissue can be used, such as with those for the treatment of or outcome history.Protein or nucleotide point From and/or purifying may not be required.

" patient " used herein refers to any vertebrate, including but not limited to mammal (such as ox, pig, camel, white horse with a black mane Camel, horse, goat, rabbit, sheep, hamster, cavy, cat, dog, rat and mouse, non-human primate, monkey, such as machin or Rhesus macaque, chimpanzee etc.) and people).

" treatment " used herein description reverses, one kind or more of the disease or the disease that mitigate or inhibit the term applicable The progress of kind symptom.Treatment can be carried out in a manner of acute or chronic.The term also refers to be reduced and the disease before with disease The seriousness of the relevant disease of disease or symptom.

" prevention " used herein includes preventing the breaking-out or prevention symptom relevant to disease of disease.

Detailed description of the invention

Fig. 1 shows the PCR qualification result figure of V kappa gene；

Fig. 2 shows the PCR qualification result figure of V λ gene；

Fig. 3 shows the PCR qualification result figure of VH gene；

Fig. 4 shows the PCR qualification result figure of scFv gene；

Fig. 5 shows the result figure that the binding specificity of anti-SFTSV-Gn albumen single-chain antibody is identified using Phage-ELISA；

Fig. 6 shows the result figure using SDS-PAGE detection antibody expression；

Fig. 7 shows the fluorogram that antibody is combined with virus；

Fig. 8 shows the fluorogram using the microneutralization of indirect immunofluorescene assay antibody；

Fig. 9 shows the optimum diluting multiple measurement chart of HRP label 4-5IgG1；

Figure 10 shows the curve graph inhibited using ELISA experimental study antibody competition.

Specific embodiment

Embodiment of the present invention is described in detail below in conjunction with embodiment.Those skilled in the art will manage Solution, the following examples are merely to illustrate the present invention, and should not be taken as limiting the scope of the invention.It is not specified in embodiment specific Technology or conditions person, described technology or conditions are (yellow such as with reference to the work such as J. Pehanorm Brooker according to the literature in the art " Molecular Cloning:A Laboratory guide " that training hall etc. is translated, the third edition, Science Press) or carry out according to product description.Examination used Production firm person is not specified in agent or instrument, and being can be with conventional products that are commercially available.

The screening of the anti-SFTSV-Gn albumen single-chain antibody of embodiment 1

1, the purifying of JS-2010-014 virion

1.1 material

JS-2010-014 was applicants in the separation acquisition in a Jiangsu patient acute stage peripheral blood in 2010.

1.2 methods and result

After virus inoculation Vero cell, in 37 DEG C, 5%CO₂Under conditions of cultivate 5 days, sterile collection supernatant is simultaneously surveyed Fixed 50% tissue infection amount (50%tissue culture infective dose, TCID50).Viral suspension is through 1:4000 β- For 24 hours in 4 DEG C of inactivations, low-speed centrifugal removes cell fragment to propiolactone, then surpasses and suspended from after 2h with PBS, through sieve chromatography technology It is further purified.The higher JS-2010-014 virion of purity can be obtained through the above steps, and all anti-virus operations are equal It is carried out in 2 grades of bio-safety laboratories (BSL-2).

2, the screening of scFv human Ab libraries building and anti-SFTSV-Gn albumen single-chain antibody

2.1 material

Primer: according to " Phage Display " book design family specificity light chain (V κ and V λ), IgG heavy chain (VH) and Overlap-PCR primer, wherein V κ 12 is right to, overlap-PCR 1 to, VH 6 to, V λ 24.

V κ forward primer:

5'-GGGCCCAGGCGGCCGAGCTCCAGATGACCCAGTCTCC-3'；

5'-GGGCCCAGGCGGCCGAGCTCGTGATGACYCAGTCTCC-3'；

5’-GGGCCCAGGCGGCCGAGCTCGTGWTGACRCAGCTCC-3’。

V κ reverse primer:

5'-GGAAGATCTAGAGGAACCACCTTTGATYTCCACCTTGGTCCC-3'；

5'-GGAAGATCTAGAGGAACCACCTTTGATCTCCAGCTTGGTCCC-3'；

5'-GGAAGATCTAGAGGAACCACCTTTAATCTCCAGTCGTGTCCC-3'；

5’-GGAAGATCTAGAGGAACCACCTTTGATATCCACTTTGGTCCC-3’。

V λ forward primer:

5'-GGGCCCAGGCGGCCGAGCTCGTGBTGACGCAGCCGCCCTC-3'；

5'-GGGCCCAGGCGGCCGAGCTCGTGCTGACTCAGCCACCCTC-3'；

5'-GGGCCCAGGCGGCCGAGCTCGCCCTGACTCAGCCTCCCTCCGT-3'；

5'-GGGCCCAGGCGGCCGAGCTCGTGCTGACTCAATCGCCCTC-3'；

5'-GGGCCCAGGCGGCCGAGCTCATGCTGACTCAGCCCCACTC-3'；

5'-GGGCCCAGGCGGCCGAGCTCGTGGTGACYCAGGAGCCMTC-3'；

5'-GGGCCCAGGCGGCCGAGCTCGTGCTGACTCAGCCACCTTC-3'；

5’-GGGCCCAGGCGGCCGAGCTCGGGCAGACTCAGCAGCTCTC-3’。

V λ reverse primer:

5'-GGAAGATCTAGAGGAACCACCGCCTAGGACGGTCASCTTGGTS-3'；

5'-GGAAGATCTAGAGGAACCACCGCCTAAAATGATCAGCTGGGTT-3'；

5’-GGAAGATCTAGAGGAACCACCGCCGAGGACGGTCAGCTSGGTS-3’。

VH forward primer:

5'-GGTGGTTCCTCTAGATCTTCCTCCTCTGGGGCGGTGGCTCGGGC-3'；

5'-GGTGGTTCCTCTAGATCTTCCTCCTCTGGTGGCGGTGGCTCGGG-3'；

5'-GGTGGTTCCTCTAGATCTTCCTCCTCTGTGGCGGTGGCTCGGGC-3'；

5'-GGTGGTTCCTCTGATCTTCCTCCTCGGTGGCGGTGGCTCGGGCG-3'；

5'-GGTGGTTCCTCTAGATCTTCCTCCTCTGGTGGCGGTGGCTCGGC-3'；

5’-GGTGGTTCCTCTAGATCTTCCTCCTCTGGTGGCGGTGGTCGGGC-3’。

VH reverse primer:

5’-CCTGGCCGGCCTGGCCACTAGTGACCGATGGGCCCTTGGTGGAR-3’。

Overlap-PCR forward primer:

5’-GAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3’。

Overlap-PCR reverse primer:

5’-GAGGAGGAGGAGGAGGAGCCTGGCCGGCCTGGCCACTAGTG-3’。

2.2 method

2.2.1 the separation of peripheral blood lymphocytes and Total RNAs extraction

By 8 SFTS patient's convalescence peripheral bloods (through Ethics Committee, applicants unit one belongs to and related blood donor Written consent) mixed respectively with the physiological saline of equivalent after according to lymphocyte separation medium specification draw mononuclearcell, it is raw Reason salt water washing is rear three times to illustrate extract RNA referring to total serum IgE extraction agent box.

2.2.2 the PCR amplification of antibody variable gene

Reverse transcription goes out the first chain of cDNA after 8 parts of total serum IgEs of extracting are mixed, and reverse transcription condition is as follows: 55 DEG C of 30min, and 85 DEG C 5min, 4 DEG C of 30min；Again using cDNA as template PCR amplifications human antibody V κ, V λ and VH gene, PCR reaction condition are as follows: 94 DEG C initial denaturation 10min, then 94 DEG C of 20s, 57 DEG C of 45s, 72 DEG C of 1min, 25 circulations, last 72 DEG C of extension 20min, gel are electric It swims and cuts glue purification recycling.

2.2.3scFv the splicing of gene

It is utilized again with VH genetic fragment mixed in equal amounts after the V kappa gene segment of purifying is mixed with V λ genetic fragment equimolar Overlap-PCR splices scFv gene, overlap-PCR reaction condition are as follows: 94 DEG C of initial denaturation 10min, then 94 DEG C of 20s, 57 DEG C 45s, 72 DEG C of 1min, 25 circulations, last 72 DEG C of extension 20min, gel electrophoresis are simultaneously cut glue purification and are recycled.

2.2.4 the building and Quality Identification in phage single-chain antibody library

ScFv gene and pComb3XSS plasmid after purification through sfiI digestion, connects glue purification purpose after the recovery respectively Segment is transferred to competent E.coli XL1-Blue, is added in 20mL 2YT culture solution and is centrifuged after 37 DEG C of culture 45min, precipitates 30 DEG C of 2YT plate are applied to be incubated overnight.The lawn grown on plate is all collected in 2YT culture medium by next day, 37 DEG C of cultures It is 0.7 to OD600.It is added final concentration of 1 × 10⁹37 DEG C of culture 45min of helper phage VCSM13 of PFU/mL.It is added eventually Concentration is that the card of 50 μ g/mL receives mycin, and 37 DEG C are continued to cultivate 7h, and 900g is centrifuged 15min and abandons precipitating, it is added 5 in supernatant × PEG/NaCl, mixing are placed on 3h on ice, and 900g is centrifuged 45min, precipitating is resuspended in the PBS of 2mL, cross 0.45 μm of filter Film, filtrate is humanized's phage single-chain antibody library, while calculating library storage capacity and diversity.

2.2.5 the screening of anti-SFTSV-Gn protein-specific single-chain antibody

Phage library after taking 100 μ L to expand is incubated for jointly with the coated SFTSV-Gn albumen of immobilization, carries out 4 wheels Screening that " absorption-elution-amplification " is affine, after taking the 4th wheel eluent to infect the Escherichia coli XL1-Blue of logarithmic growth phase, coating 2 × YT culture plate, 37 DEG C of overnight incubations, 200 single colonies of random picking are inoculated with 96 hole deep-well plates (containing 100 μ g/mL ammonia benzyls respectively Penicillin, 12.5 μ g/mL tetracyclines and 1g/mL glucose), 37 DEG C shaking culture, next day 1:10 are inoculated into new 96 respectively overnight 5h is cultivated in 37 DEG C of shakings in hole deep-well plates (containing 100 μ g/mL ampicillins and 12.5 μ g/mL tetracyclines), and helper phage is added Body VCSM13 (final concentration of 1 × 10⁹PFU/mL), 37 DEG C of incubation 1h are added card and receive 30 DEG C of mistakes of mycin (final concentration of 50 μ g/mL) Night shaking culture is prepared into phage single-chain antibody, and with 0.1 hole μ g/ SFTSV-Gn albumen coated elisa plate, secondary antibody is slow with PBS Fliud flushing (skimmed milk power containing 5g/mL) marks anti-M13 antibody by the diluted HRP of 1:2000, carries out Phage-ELISA identification and measures OD450 value, the positive is set to as Positive/Negative >=2.1, and the bacterium solution of positive colony send Shanghai Sangon Biotech Company to be sequenced.

2.3 result

2.3.1 the identification of human antibody V κ, V λ and VH gene

Go out 12 sizes about 350bp target fragment using 12 pairs of V kappa gene primer amplifications, the result is shown in Figure 1, wherein M:DNA marker；1-12:PCR product；13: negative control.The piece of 24 sizes about 350bp mesh is amplified using 24 pairs of V λ gene primers Section, is as a result shown in Fig. 2, wherein M:DNA marker；1: negative control；2-25:PCR product.It is amplified using 6 pairs of VH gene primers 6 sizes about 400bp target fragment, is as a result shown in Fig. 3, wherein M:DNA marker；1-6:PCR product；7: negative control.As a result It is consistent with expection.

2.3.2scFv the splicing of antibody gene

Spliced at random using overlap-PCR and obtained the target fragment of 750bp or so, as a result sees Fig. 4, wherein M:DNA marker；1-3:overlap-PCR product；4: negative control.As a result it is consistent with expection.

2.3.4 the screening of anti-SFTSV-Gn albumen single-chain antibody

The 4 affine screenings of wheel have been carried out to humanization SFTSV virus single chain antibody library using SFTSV-Gn albumen as antigen, have been resisted SFTSV-Gn protein-specific single-chain antibody has obtained selective enrichment, and output/investment ratio improves 30 times (tables 1).At random 200 bacteriophage monoclonals of picking carry out Phage-ELISA test and measure OD450 value, there is 19 single-chain antibodies as the result is shown (Fig. 5) can be specifically bound with SFTSV-Gn albumen.19 positive colony bacterium solutions obtain 3 kinds of different aminoacids through sequencing analysis The scFv antibody of sequence, is respectively designated as 4-6,2F6,1B2；4-6 antibody weight, light chain variable region nucleic acid and the following institute of protein sequence Show:

The amino acid sequence of 4-6 antibody heavy chain variable region such as SEQ ID NO:7, nucleic acid sequence such as SEQ ID NO:12 institute Show；The amino acid sequence of heavy chain variable region CDR1 such as SEQ ID NO:1, nucleic acid sequence is as shown in SEQ ID NO:9；Weight chain variable The amino acid sequence of area CDR2 such as SEQ ID NO:2, nucleic acid sequence is as shown in SEQ ID NO:10；The ammonia of heavy chain variable region CDR3 Base acid sequence such as SEQ ID NO:3, nucleic acid sequence is as shown in SEQ ID NO:11.

The amino acid sequence of 4-6 antibody's light chain variable region such as SEQ ID NO:8, nucleic acid sequence such as SEQ ID NO:16 institute Show；The amino acid sequence of light chain variable region CDR1 such as SEQ ID NO:4, nucleic acid sequence is as shown in SEQ ID NO:13；Light chain can Become the amino acid sequence such as SEQ ID NO:5 of area CDR2, nucleic acid sequence is as shown in SEQ ID NO:14；Light chain variable region CDR3's Amino acid sequence such as SEQ ID NO:6, nucleic acid sequence is as shown in SEQ ID NO:15.

Table 1 is affine, and screening fights the enrichment effect of SFTSV-Gn protein-specific scFv antibody

Number of screening round	Put into the titre (PFU) of scFv	The titre (PFU) of output scFv	Output/investment
				The first round	5×1012	6×105	1.20×10-7
Second wheel	3.6×1012	4×105	1.11×10-7
				Third round	2.4×1012	8×105	3.33×10-7
Fourth round	2.1×1012	7.5×106	3.57×10-6

The full molecularization building of embodiment 2scFv antibody and eukaryotic expression

1, the building of baculoviral recombinant plasmid

PCR amplification VH, VL gene, each amplification system are distinguished by template of tri- kinds of single-chain antibody plasmids of 4-6,2F6,1B2 It include the following contents: 10 μ L of scfv plasmid 0.1 μ g, upstream primer 60pmol, downstream primer 60pmol, 10 × PCR buffer, DNTP 8 μ L, MgCl₂6 μ L, Ex Taq, 0.5 μ L, adds water to 100 μ L.Reaction condition are as follows: 94 DEG C of 5min；94 DEG C of 15sec, 56 DEG C 30sec, 72 DEG C of 1min, 30 circulations；72℃10min.Plastic recovery kit recycles purpose band.By above-mentioned PCR product, divide Digestion, while eukaryon rhabdovirus expression vector plasmid pAc-K- are not carried out with XhoI/NheI (VH), SacI/HindIII (Vk) CH3 first carries out XhoI/NheI digestion, after the insertion of VH segment, then carries out SacI/HindIII digestion, is inserted into VL segment.Digestion Not it is are as follows: DNA 10 μ each 10u of g, XhoI/NheI or SacI/HindIII, 10 × enzyme cutting buffering liquid, 10 μ L add water to 100 μ L. 37 DEG C of digestion 20h.1% agarose gel electrophoresis cuts purpose band, carries out glue recycling.16 DEG C of glue recovery product of connection is overnight. Connection product converts bacillus coli DH 5 alpha, identifies positive colony (as described above) by PCR, there is gram of insertion for VH and VL It is grand, the recombinant plasmid that about 10 μ g are purified is prepared with the plasmid extraction kit of Qiagen company.

2, expression of the whole antibody molecule in insect cell

Using the BaculoGold cotransfection kit of pharmingen company, by Transfected Recombinant Plasmid 293T cell.27 DEG C culture 4-5 days after, observation infection conditions；Infection supernatant is collected after 5 days, obtains recombinant virus.Plaque purification and recombinant virus After 293T cell is reached 24 orifice plates by amplification, recombinant virus infection is used.27 DEG C culture 4-5 days after harvest supernatant.2000rpm centrifugation 10min removes cell fragment.By loading after the protein expression supernatant of the harvest miillpore filter of 0.45 μ L to GE The proteinA affinity column of Healthcare；PBS is washed till baseline.Eluent (Gly-HCl of 0.1mol/L, pH2.7) is washed It is de-, pH7.0 is neutralized to the Tris of 1mol/L；Sample row SDS-PAGE detection to purifying, observes purity.As a result such as Fig. 6 institute Show, wherein 1:4-6 monoclonal antibody is non-reduced, and the reduction of 2:4-6 monoclonal antibody, 3:1B2 monoclonal antibody is non-reduced, the reduction of 4:1B2 monoclonal antibody, 5:2F6 monoclonal antibody It is non-reduced, 6:2F6 monoclonal antibody reduction, 7: albumen Marker, purify acquisition whole immunoglobulin be named as 4-6IgG1,2F6IgG1, 1B2IgG1。

3 whole immunoglobulin of embodiment and SFTSV Binding experiment

1, method

(1) by Vero cell inoculation in 24 orifice plates, 37 DEG C of cultures, every hole virus inoculation liquid when fusion rate reaches 90%.

(2) two days later, virus liquid is removed, 400 μ l, 4% paraformaldehyde, the fixed 30min of room temperature is added in every hole.

(3) paraformaldehyde is discarded, is cleaned 3 times with PBS, 400 μ l 0.2%Triton X-100 permeabilized cells films, room is added Warm 15min.

(4) Triton X-100 is discarded, is cleaned 3 times with PBS, the BSA that 5mg/ml is added is closed, room temperature 30min.

(5) confining liquid is discarded, the full molecule monoclonal antibody of 300 μ l after purification is added in every hole, multiple holes is arranged, while setting is added without The blank control group and 4-5IgG1 monoclonal antibody of antibody are (referring to patent document: a kind of human antibody of anti-SFTSV, Authorization Notice No. CN 102942629B) positive controls, in 37 DEG C of incubation 1h.

(6) primary antibody is removed, 500 μ l PBST are added, cleans 3 times, 500 revs/min, shakes 5min.

(7) anti-human igg of FITC label is added, 37 DEG C are protected from light incubation 30min.

(8) secondary antibody is removed, 500 μ l PBST are added and clean 3 times, 500 revs/min, shake 5min.

(9) fluorescence microscopy microscopic observation.

2, result

4-6IgG1,2F6IgG1,1B2IgG1 combination with higher in conjunction with SFTSV are active (Fig. 7).

The full molecule monoclonal antibody microneutralization of embodiment 4 experiment

1, method

(1) Vero cell inoculation is in 96 orifice plates, virus inoculation antibody complex when cell confluency reaches 90%.

(2) equivalent 100TCID50 virus and antibody (100 μ g/ml) are mixed, 37 DEG C of incubation 1h.

(3) culture solution is discarded, 100 μ l compounds are added in every hole, and 37 DEG C of incubation 2h are arranged multiple holes, while being arranged without antibody Group, virus-free group and 4-5IgG1 positive controls.

(4) compound is discarded, 100 μ l maintaining liquids, 37 DEG C of culture 48h are added in every hole.

(5) maintaining liquid is removed, 200 μ l, 4% paraformaldehyde, the fixed 30min of room temperature is added in every hole.

(6) paraformaldehyde is discarded, is cleaned 3 times with PBS, 200 μ l 0.2%Triton X-100 permeabilized cells films, room is added Warm 15min.

(7) Triton X-100 is discarded, PBS is cleaned 3 times, and the BSA that 5mg/ml is added is closed, room temperature 30min.

(8) confining liquid is discarded, the primary antibody of anti-NP, every hole 100 μ l, 37 DEG C of incubation 1h is added.

(9) primary antibody is removed, 200 μ l PBST are added and clean 3 times, 500 revs/min, shake 5min.

(10) the anti-human secondary antibody of 100 μ l FITC label is added, 37 DEG C are protected from light incubation 30min.

(11) secondary antibody is removed, 500 μ l PBST are added and clean 3 times, 500 revs/min, shake 5min.

(12) fluorescence microscopy microscopic observation.

2, result

Microneutralization experimental result shows that 4-6IgG1,2F6IgG1,1B2IgG1 all have neutralization (figure to SFTSV 8)。

5 monoclonal antibody Preliminary Analysis of Antigenic Epitopes of embodiment

1, HRP marks the measurement of 4-5IgG1 optimum diluting multiple

With the SFTSV-Gn albumen coated elisa plate (hole 100ng/) of purifying, mark 4-5IgG1 from 1:100~1 HRP: 600 start to dilute, board-washing after 100 37 DEG C of the hole μ L/ incubation 1h, and TMB colour developing measures OD450 value, select OD450 value 1.0~ That HRP label 4-5IgG1 dilution between 1.5 is optimum diluting multiple.As a result, it has been found that when being diluted according to 1:300, OD450 It is worth (1.363) between 1.0~1.5 (Fig. 9), therefore 1:300 is selected to mark 4-5IgG1 optimum diluting multiple for HRP.

2, competitive ELISA tests 3 kinds of monoclonal antibody epitopes of preliminary analysis

Working solution made of 1:300 is pressed by 4-5IgG1,4-6IgG1,2F6 IgG1,1B2 with HRP label 4-5IgG1 respectively Since 100ng, doubling dilution is at war with ELISA experiment for IgG1, anti-SFTSV-NP monoclonal antibody (irrelevant antibody as control), and It reads OD450 and draws competition inhibition curve, experimental result shows (Figure 10), with 4-6IgG1,2F6 IgG1,1B2 IgG1 times Than dilution, there is no significant changes for OD450 value, illustrate 4-6IgG1,2F6 IgG1,1B2 IgG1 SFTSV- in conjunction with 4-5IgG1 Gn albumen does not repel mutually, without competitive relation, shows the epitope and 4-5IgG1 of 4-6IgG1,2F6 IgG1,1B2 IgG1 It is not identical.

Although those skilled in the art should manage above only describes a specific embodiment of the invention example Solution, these are merely examples, and protection scope of the present invention is defined by the appended claims.Those skilled in the art Without departing from the principle and essence of the present invention, many changes and modifications may be made, but this A little changes or modification each fall within protection scope of the present invention.

Sequence table

<110>Jiangsu Prov. Disease Preventing and Controlling Center (public health research institute, Jiangsu Province)

<120>SFTSV inhibitor and its application

<160> 16

<170> SIPOSequenceListing 1.0

<210> 1

<211> 8

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 1

Gly Asp Ser Phe Thr Asn Tyr Trp

1 5

<210> 2

<211> 8

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 2

Ile Phe Leu Gly Asp Ser Asp Thr

1 5

<210> 3

<211> 20

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 3

Ala Arg Leu Lys Leu Arg Gly Phe Cys Thr Gly Asp Thr Cys Asn Arg

1 5 10 15

Trp Phe Asp Pro

20

<210> 4

<211> 9

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 4

Asn Ser Asp Ile Gly Asn Tyr Asn Phe

1 5

<210> 5

<211> 9

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 5

Glu Val Ser Lys Arg Pro Ser Gly Val

1 5

<210> 6

<211> 10

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 6

Ser Ser Tyr Gly Gly Asn Asn Asn Leu Leu

1 5 10

<210> 7

<211> 160

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 7

Gly Gly Ser Ser Arg Ser Ser Ser Ser Gly Gly Gly Gly Ser Gly Gly

1 5 10 15

Gly Gly Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro

20 25 30

Gly Glu Ser Leu Lys Ile Ser Cys Lys Gly Ala Gly Asp Ser Phe Thr

35 40 45

Asn Tyr Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu

50 55 60

Trp Met Gly Ser Ile Phe Leu Gly Asp Ser Asp Thr Arg Tyr Ser Pro

65 70 75 80

Ser Phe Gln Gly Gln Val Thr Ile Ser Ala Asp Arg Ser Ile Gln Thr

85 90 95

Ala Tyr Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr

100 105 110

Tyr Cys Ala Arg Leu Lys Leu Arg Gly Phe Cys Thr Gly Asp Thr Cys

115 120 125

Asn Arg Trp Phe Asp Pro Trp Gly Gln Gly Thr Leu Val Thr Val Thr

130 135 140

Pro Ala Ser Thr Lys Gly Pro Ser Val Thr Ser Gly Gln Ala Gly Gln

145 150 155 160

<210> 8

<211> 116

<212> PRT

<213>artificial sequence (Artificial Sequence)

<400> 8

Val Ala Gln Ala Ala Glu Leu Ala Leu Thr Gln Pro Pro Ser Val Ser

1 5 10 15

Gly Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Asn Ser

20 25 30

Asp Ile Gly Asn Tyr Asn Phe Val Ser Trp Tyr Gln Gln Tyr Pro Gly

35 40 45

Lys Ala Pro Lys Pro Leu Ile Tyr Glu Val Ser Lys Arg Pro Ser Gly

50 55 60

Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu

65 70 75 80

Thr Val Thr Gly Leu Gln Thr Asp Asp Glu Ala Asp Tyr Tyr Cys Ser

85 90 95

Ser Tyr Gly Gly Asn Asn Asn Leu Leu Phe Gly Gly Gly Thr Lys Leu

100 105 110

Thr Val Leu Gly

115

<210> 9

<211> 24

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 9

ggagacagtt ttaccaatta ctgg 24

<210> 10

<211> 24

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 10

atctttcttg gtgactctga cacc 24

<210> 11

<211> 60

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 11

gcgagactca aattacgagg attttgtact ggtgacacct gcaacaggtg gttcgacccc 60

<210> 12

<211> 480

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 12

ggtggttcct ctagatcttc ctcctctggt ggcggtggct cgggcggtgg tgggcaggtg 60

cagctggtgc agtctggggc tgaggtgaaa aagcccgggg agtctctgaa aatctcctgt 120

aagggtgctg gagacagttt taccaattac tggatcggct gggtgcgcca gatgcccggg 180

aaaggcctgg agtggatggg gagcatcttt cttggtgact ctgacaccag atacagtccg 240

tccttccaag gccaggtcac catctcagcc gacaggtcca tccaaaccgc ctatttgcaa 300

tggagcagtc tgaaggcctc ggacaccgcc atgtactact gtgcgagact caaattacga 360

ggattttgta ctggtgacac ctgcaacagg tggttcgacc cctggggcca gggaaccctg 420

gtcaccgtca ccccggcttc caccaagggc ccatcggtca ctagtggcca ggccggccag 480

<210> 13

<211> 27

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 13

aacagtgaca ttggtaatta taacttt 27

<210> 14

<211> 27

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 14

gaggtcagta agaggccctc aggggtc 27

<210> 15

<211> 30

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 15

agctcatatg gaggcaacaa taatttgctt 30

<210> 16

<211> 348

<212> DNA

<213>artificial sequence (Artificial Sequence)

<400> 16

gtggcccagg cggccgagct cgccctgact cagcctccct ccgtgtccgg gtctcctgga 60

cagtcagtca ccatttcctg cactggaacc aacagtgaca ttggtaatta taactttgtc 120

tcttggtacc aacagtaccc agggaaagcc cccaaaccct tgatttatga ggtcagtaag 180

aggccctcag gggtccctga tcgcttctct ggctccaagt ctggcaacac ggcctccctg 240

accgtcactg ggctccagac tgatgatgag gctgattatt actgcagctc atatggaggc 300

aacaataatt tgcttttcgg cggaggcacc aagttgaccg tcctaggt 348

Claims (10)

1. a kind of isolated SFTSV inhibitor, which is characterized in that the SFTSV inhibitor includes:

(1) shown in heavy chain CDR2, SEQ ID NO:3 shown in heavy chain CDR1, SEQ ID NO:2 shown in SEQ ID NO:1 Heavy chain CDR3；And/or

(2) shown in light chain CDR2, SEQ ID NO:6 shown in light chain CDR1, SEQ ID NO:5 shown in SEQ ID NO:4 Light chain CDR3.

Preferably, the SFTSV inhibitor includes:

(1) heavy chain variable region, the heavy chain variable region have amino acid sequence shown in SEQ ID NO:7；And/or

(2) light chain variable region, the light chain variable region have amino acid sequence shown in SEQ ID NO:8.

2. encoding the nucleic acid molecules of SFTSV inhibitor described in claim 1；Preferably, the nucleic acid molecules of encoding heavy chain CDR1 Sequence is as shown in SEQ ID NO:9, and the sequence of nucleic acid molecules of encoding heavy chain CDR2 is as shown in SEQ ID NO:10, encoding heavy chain The sequence of nucleic acid molecules of CDR3 is as shown in SEQ ID NO:11, the sequence of nucleic acid molecules of encoding heavy chain variable region such as SEQ ID NO: Shown in 12；The sequence of nucleic acid molecules of light chain CDR1 is encoded as shown in SEQ ID NO:13, encodes the nucleic acid molecules sequence of light chain CDR2 Column encode the sequence of nucleic acid molecules of light chain CDR3 as shown in SEQ ID NO:15 as shown in SEQ ID NO:14, and coding light chain can Become the sequence of nucleic acid molecules in area as shown in SEQ ID NO:16.

3. a kind of recombinant vector including nucleic acid molecules as claimed in claim 2；The recombinant vector includes described in claim 2 Nucleic acid molecules.

4. a kind of recombinant cell including nucleic acid molecules as claimed in claim 2 or recombinant vector as claimed in claim 3.

5. a kind of pharmaceutical composition of the SFTSV inhibitor described in claim 1 including therapeutically effective amount.

6. pharmaceutical composition according to claim 5, which is characterized in that described pharmaceutical composition includes pharmaceutically acceptable Carrier.

7. a kind of testing product or immunoconjugates including SFTSV inhibitor described in claim 1.

8. a kind of method of the detection SFTSV level of non-diagnostic purpose, which is characterized in that the method includes containing SFTSV Sample contacted with SFTSV inhibitor described in claim 1.

9. the application of SFTSV inhibitor described in claim 1, the application includes any one of following:

(1) application in testing product as claimed in claim 7 or immunoconjugates is being prepared；

(2) application in pharmaceutical composition described in claim 5 or 6 is being prepared；

(3) application in SFTSV activity or horizontal drug is adjusted in preparation；

(4) application in preparation and in the drug of SFTSV virulence；

(5) application in the drug for preparing anti-SFTSV infection；

(6) application in the drug of disease caused by being infected in preparation prevention or treatment by SFTSV.

10. the application of pharmaceutical composition as claimed in claim 6, the application includes any one of following:

(1) application in SFTSV activity or horizontal drug is adjusted in preparation；

(2) application in preparation and in the drug of SFTSV virulence；

(3) application in the drug for preparing anti-SFTSV infection；

(4) application in the drug of disease caused by being infected in preparation prevention or treatment by SFTSV.